Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diphencyprone + PD-1/PD-L1 ICI in Advanced Cancer With Cutaneous Metastases
NCT05481658Phase 1Recruiting
- Start
- Oct 2022
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of diphencyprone in cancer and cutaneous metastasis (CM). Primary endpoint: Proportion of subjects with a grade 3 adverse event at Day 128. Started Oct 2022; status: recruiting.
02
Drugs
diphencyprone
03
Conditions
cancercutaneous metastasis (CM)
Beyond the preview
Go deeper on NCT05481658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481658.